Orchestra Therapeutics

5 articles about Orchestra Therapeutics

• Orchestra BioMed™ Enhances Management Team with Appointment of Regulatory Affairs and Combination Product Expert Bob Laughner as Vice President, Regulatory Affairs

  4/28/2020

  Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Bob Laughner, an expert in global regulatory affairs for combination products, as Vice President, Regulatory Affairs. Mr. Laughner will play a lead role in advancing Orchestra BioMed’s Virtue ®  Sirolimus AngioInfusion ™

• Carlsbad Biotech Company, Orchestra Therapeutics Files Bankruptcy

  10/16/2008

• Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program

  7/18/2007

• Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax(TM) Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

  6/11/2007

• Orchestra Therapeutics Announces New Trading Symbol

  4/16/2007